Trial Profile

First-in-man Clinical Trial to Assess Safety and Tolerability of CEB-01 PLGA Membrane in Patients With Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma After Surgery

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SN 38 (Primary)
Indications Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Soft tissue sarcoma; Solitary-fibrous-tumour
Focus Adverse reactions; First in man
Sponsors Cebiotex

Most Recent Events

04 Jun 2024 Results (n=14) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
27 Mar 2024 Planned End Date changed from 15 Mar 2024 to 15 May 2025.
27 Mar 2024 Planned primary completion date changed from 15 Dec 2023 to 15 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com